Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX)

Thrivent Financial for Lutherans purchased a new position in Nkarta, Inc. (NASDAQ:NKTX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 103,551 shares of the company’s stock, valued at approximately $258,000. Thrivent Financial for Lutherans owned 0.15% of Nkarta at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Catalina Capital Group LLC lifted its stake in shares of Nkarta by 57.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock valued at $47,000 after buying an additional 6,867 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in Nkarta during the fourth quarter valued at about $31,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Nkarta in the fourth quarter valued at about $37,000. State Street Corp boosted its stake in shares of Nkarta by 1.4% in the third quarter. State Street Corp now owns 1,098,062 shares of the company’s stock worth $4,963,000 after acquiring an additional 15,569 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Nkarta during the third quarter worth about $74,000. 80.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on NKTX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus lowered their target price on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $14.86.

Nkarta Stock Down 4.4 %

NKTX stock opened at $1.63 on Friday. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $9.70. The stock has a market capitalization of $115.66 million, a price-to-earnings ratio of -0.87 and a beta of 0.83. The firm’s fifty day simple moving average is $1.92 and its two-hundred day simple moving average is $2.72.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, equities research analysts expect that Nkarta, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.70% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.